Annual Report 2020

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2020 147 The United Laboratories International Holdings Limited Annual Report 2020 42. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES The table below details changes in the Group’s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group’s consolidated statement of cash flows as cash flows from financing activities. Convertible Lease Dividend Borrowings bonds liabilities payable Total RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 (Note 29) (Note 30) (Note 28) (Note 15) At 1 January 2019 3,208,954 830,894 119,305 – 4,159,153 Financing cash flows 574,131 (37,924) (120,093) (98,383) 317,731 Derecognition of bills receivables (16,019) – – – (16,019) Conversion of convertible bond – (8,337) – – (8,337) Fair value change – 110,117 – – 110,117 Finance costs 185,240 97,356 2,551 – 285,147 Dividend declared – – – 98,383 98,383 Exchange loss 35,683 16,327 – – 52,010 At 31 December 2019 3,987,989 1,008,433 1,763 – 4,998,185 Financing cash flows (1,765,948) (13,226) (1,721) (128,140) (1,909,035) Derecognition of bills receivables (61,793) – – – (61,793) Conversion of convertible bond – (1,361,364) – – (1,361,364) Fair value change – 314,614 – – 314,614 Finance costs 145,953 42,981 80 – 189,014 Dividend declared – – – 128,140 128,140 Exchange (gain) loss (96,550) 8,562 – – (87,988) Non-cash changes – New Leases entered – – 1,800 – 1,800 – Lease modification – – (236) – (236) At 31 December 2020 2,209,651 – 1,686 – 2,211,337